Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VELAGLUCERASE ALFA Cause Product dose omission issue? 188 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 188 reports of Product dose omission issue have been filed in association with VELAGLUCERASE ALFA (VPRIV). This represents 10.8% of all adverse event reports for VELAGLUCERASE ALFA.

188
Reports of Product dose omission issue with VELAGLUCERASE ALFA
10.8%
of all VELAGLUCERASE ALFA reports
15
Deaths
83
Hospitalizations

How Dangerous Is Product dose omission issue From VELAGLUCERASE ALFA?

Of the 188 reports, 15 (8.0%) resulted in death, 83 (44.1%) required hospitalization, and 6 (3.2%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VELAGLUCERASE ALFA. However, 188 reports have been filed with the FAERS database.

What Other Side Effects Does VELAGLUCERASE ALFA Cause?

Inappropriate schedule of product administration (197) Covid-19 (163) Fatigue (136) Death (108) Fall (104) Pyrexia (101) Malaise (98) Weight increased (89) Headache (88) Arthralgia (84)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which VELAGLUCERASE ALFA Alternatives Have Lower Product dose omission issue Risk?

VELAGLUCERASE ALFA vs VELCADE VELAGLUCERASE ALFA vs VELETRI VELAGLUCERASE ALFA vs VELIPARIB VELAGLUCERASE ALFA vs VEMURAFENIB VELAGLUCERASE ALFA vs VENETOCLAX

Related Pages

VELAGLUCERASE ALFA Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue VELAGLUCERASE ALFA Demographics